In the STABLED randomized clinical trial of 249 patients with nonvalvular atrial fibrillation and a recent ischemic stroke, adding catheter ablation to standard anticoagulation therapy with edoxaban did not significantly reduce the composite risk of recurrent ischemic stroke, systemic embolism, all-cause death, or hospitalization for heart failure compared with standard therapy alone during a median follow-up of more than 3 years. Event rates were lower than anticipated in both groups, suggesting the trial may have been underpowered to detect clinically meaningful differences in secondary stroke prevention.

Source: JAMA Neurology